Search results
SGLT2 beyond diabetes
Added:
4 years ago
Video
Added:
3 years ago
There has been an increase in the prevalence of diabetes mellitus over the past 40 years, both in the US and worldwide. The worldwide prevalence of diabetes in 2000 was approximately 2.8% and is estimated to grow to 4.4% by 2030. This translates to a projected rise of diabetes from 171 million in 2000 to well over 350 million in 2030. The epidemic of diabetes will continue to rise as there is…
View more
Added:
4 years ago
In this video, Prof Lars Lund, Professor of Medicine and Cardiology (Karolinska Institute, Stockholm, SE) discusses the emerging data on SGLT2 inhibitors.
This interview is a component of a wider Radcliffe Education programme entitled,'Current and emerging data on SGLT2 inhibitors in heart failure'. Certified accreditation of the full programme is pending following application to the European…
View more
Added:
3 years ago
Introduction
Diabetes mellitus (DM), characterised by chronic hyperglycaemia, is a rapidly growing worldwide health problem. The prevalence of DM has been estimated at 3% to 5% of Western populations. The incidence of DM is increasing and will more than double within 15 years, mainly due to adverse lifestyle changes with excess caloric intake and reduced physical activity, which in turn will…
View more
Added:
3 years ago
Diabetes mellitus (DM) is a group of diseases characterised by metabolic disturbances with increasing prevalence worldwide.1 Individuals with DM present several detrimental micro- and macrovascular complications such as retinopathy, nephropathy, neuropathy, atherosclerosis and coronary heart disease.2,3 Accordingly, efforts for early diagnosis and appropriate management are of ultimate importance…
View more
Added:
3 years ago
The increasing worldwide prevalence of diabetes mellitus (DM) means almost 360 million people are suffering from this disease (in 2011) and it is estimated to reach 552 million people by 2030.1 The latest European Action on Secondary Prevention by Intervention to Reduce Events (EuroASPIRE) study (2013) has revealed that the mean prevalence of DM in European patients with coronary artery disease …
View more
Added:
1 year ago
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University,CA) is joined by Dr Neha J Pagidipati (Duke University Medical Center, US)and Dr Christopher B Granger (Duke University Medical Center, US)to discuss the results of the COORDINATE-Diabetes trial (NCT03936660).The COORDINATE-Diabetes trial is testing a multifaceted intervention to improve the care of people with type 2…
View more
Added:
6 years ago
Gemma Figtree discusses the CANVAS trial - canagliflozin and heart failure in type 2 diabetes mellitus.
Filmed by Radcliffe Cardiology on-site at the American College of Cardiology congress 2018 in Orlando, USA.
View more
Added:
6 months ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants…
View more
Added:
6 years ago
This video was supplied by the International Society of Cardiovascular Pharmacotherapy (ISCP) and discusesCardiovascular risk management of diabetes and SGLT2 inhibitors
Lecturer: Masayuki Yoshida, Professor of Medicine, Tokyo Medical and Dental University, Japan
Interviewer： Koji Hasegawa, Leader, Cardiovascular Clinical Research Network, National Hospital Organization,Shizuoka, Japan
View more
